Background Lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) may play a role in plaque progression and vulnerability. We aimed to define plaque characteristics on multimodality intravascular imaging in patients with coronary endothelial dysfunction in response to long-term inhibition of Lp-PLA2 by darapladib.
Background Lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) may play a role in plaque progression and vulnerability. We aimed to define plaque characteristics on multimodality intravascular imaging in patients with coronary endothelial dysfunction in response to long-term inhibition of Lp-PLA2 by darapladib.
Patients and methods This is a double-blinded, randomized study screening 70 patients, and enrolling 54 patients with suspected ischemia, without obstructive disease on angiography and with coronary endothelial dysfunction by invasive assessment. Patients were randomized to receive darapladib or placebo for 6 months. Forty patients underwent multimodality intravascular imaging at baseline and after 6 months of therapy. Several parameters of plaque vulnerability were measured, including maximum value of lipid core burden index for any of the 4-mm segment (maxLCBI 4 mm ) by near-infrared spectroscopy. Microchannels and macrophages were assessed using optical coherence tomography and necrotic core volume by virtual histology intravascular ultrasound.
Results There was no significant difference in maxLCBI 4 
Introduction
Lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) is a novel biomarker for vascular wall inflammation, which is bound to both low-density and high-density lipoproteins and has been shown to promote vascular inflammation [1] . Epidemiological studies have suggested that Lp-PLA 2 is a potential independent risk factor for cardiovascular events [2] [3] [4] [5] [6] possibly through a causative role in the atherosclerotic process, explaining the increased cardiovascular morbidity and mortality seen with increased Lp-PLA 2 levels. Moreover, Lp-PLA 2 may play a role in vascular inflammation in the early stage of atherosclerosis, as it has been directly related to the extent of atheroma and strongly associated with coronary endothelial function [7] [8] [9] . This suggests a potential mechanistic link between inflammation, coronary endothelial function, and Lp-PLA 2 levels in early atherosclerosis.
Darapladib, a selective reversible Lp-PLA 2 inhibitor, was developed with the goal of targeting Lp-PLA 2 and reducing cardiovascular events. Previous studies demonstrated that inhibition of Lp-PLA 2 in the animal model of advanced atherosclerosis attenuated plaque progression [10] and the progression of necrotic core in patients with coronary atherosclerosis [11] . However, the effect of darapladib on early atherosclerosis has yet to be further explored.
The current study was designed to assess the role of Lp-PLA 2 in coronary plaque progression and stability in patients with early coronary atherosclerosis. We hypothesized that in patients with early coronary atherosclerosis, structural and mechanical properties reflecting plaque vulnerability may be attenuated with darapladib. To this end, the present study investigated the changes in coronary plaque characteristics Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website, www.coronary-artery.com.
related to Lp-PLA 2 inhibition using intravascular imaging, including near-infrared spectroscopy (NIRS), optical coherence tomography (OCT), and virtual histology intravascular ultrasound (VH-IVUS).
Patients and methods

Study design
This study was a single-center, National Institutes of Health-funded, phase III, randomized, double-blinded controlled trial, performed between February 2010 and February 2015, that evaluated the effect of darapladib (GlaxoSmithKline, Brentford, UK), an Lp-PLA 2 inhibitor, on plaque characteristics suggestive of plaque vulnerability. All patients provided informed consent and the Mayo Institutional Review Board approved the study protocol (Clinicaltrials.gov Identifier: NCT01067339).
Patients enrolled underwent baseline laboratory testing, including fasting lipid panel, liver and renal function testing, and index coronary angiography with intravascular imaging and were then randomized by a statistical program to darapladib 160 mg taken by mouth once per day or placebo produced by pharmacy. Patients were followed for 6 months and then re-evaluated on follow-up with coronary angiography including intravascular imaging and repeat laboratory testing.
Study population
Patients were enrolled from the Chest Pain and Coronary Physiology Clinic as well as the outpatient and inpatient practices in the Cardiovascular Department at Mayo Clinic Rochester. Eligibility criteria included patients older than 18 years and younger than 85 years, with a clinical indication for index coronary angiography and no significant coronary disease noted on angiography. Exclusion criteria included heart failure; ejection fraction less than 40%; unstable angina; myocardial infarction or angioplasty within 6 months before entry into the study; use of investigational agents within 1 month of entry into the study; patients who required treatment with positive inotropic agents other than digoxin during the study; patients with cerebrovascular accident within 6 months before entry the study; significant endocrine, hepatic or renal disorders; local or systemic infectious disease within 4 weeks before entry into study; pregnancy or lactation; mental instability; and Federal Medical Center inmates.
Seventy patients were screened, and of these, five withdrew before randomization. Sixty-five patients were randomized to either the placebo arm (n = 34) or the darapladib arm (n = 31). During the study period, five patients withdrew from the placebo arm and six patients from the darapladib arm. Of the remaining patients, a subset of 40 patients, 21 in the placebo arm and 19 in the darapladib arm, underwent concomitant intracoronary imaging at baseline and followup. There were no significant differences between reasons for withdrawal from both arms. Reasons included needing spinal cord stimulator because of continued refractory angina and ineffectiveness of traditional clinical medications, concern that participation in the study would put professional federal aviation licensure in jeopardy, and logistic concerns with travel to and from the clinic.
NIRS, OCT, and VH-IVUS were performed for at least mild lesions of the left anterior descending (LAD) artery. At 6 months, NIRS, OCT, and VH-IVUS examinations were repeated in the same segments as those imaged at baseline. All images were analyzed within an independent core laboratory at Mayo Clinic. Image review and analysis were performed by independent examiner who was blind to clinical characteristics and treatment arm.
Near-infrared spectroscopy
A coronary artery segment was identified between the proximal and mid-LAD using distance from anatomical landmarks such as side branches that are seen on angiography. We have previously reported the presence of lipid core in patients with early coronary atherosclerosis [12] . Subsequently, for each identified segment, NIRS examination was performed. The NIRS system consists of 3.2-Fr, 160-cm rapid exchange catheter (LipiScan; InfraReDx, Burlington, Massachusetts, USA), a motorized pullback device, and a console [12] [13] [14] . NIRS catheter was introduced into the LAD over a 0.014-inch coronary guidewire and pulled back using an automated mechanical pullback and rotation device at a speed of 0.5 cm/s and 240 rotation/m until the NIRS catheter was withdrawn into the guiding catheter. The NIRS images and the block chemograms were recorded into a compact disk for offline quantitative analysis. The analysis was performed using the LipiScan analyzer software (LipiScan; InfraReDx). The NIRS system acquires about 1000 NIRS measurement/12.5 cm of artery scanned and determines the presence of lipid core plaque (LCP) at each interrogated location in the artery using a predictive algorithm. The calculated data are displayed in a twodimensional map of the vessel (chemogram). The x-axis of the chemogram represents the pullback position in millimeter scale and the y-axis represents the circumferential position in degrees (0°-360°); a color scale from red to yellow indicates increasing algorithm probability that an LCP is present [12, 13] . From the chemogram, a summary metric of the probability that an LCP is present in a 2-mm interval of pullback is computed and displayed in a color map called a 'block chemogram'. The block chemogram is mapped to the same color scale as the chemogram, but the display is binned to four discrete colors to aid visual interpretation (red: P < 0.57, orange: 0.57 ≤ P ≤ 0.84, tan: 0.84 ≤ P ≤ 0.98, yellow: P > 0.98, algorithm probability that an LCP is present in that 2 mm block). To provide a quantitative summary metric of the LCP presence in the entire scanned segment, the lipid core burden index (LCBI) was calculated, which is the fraction of valid pixel in the chemogram that exceeds an LCP probability of 0.6, multiplied by 1000. Because LCBI is dependent on the length of the artery scanned, LCBI per length of the scanned artery (LCBI/L) was also analyzed in the present study. The maxLCBI 4 mm was defined as the maximum value of the LCBI for any of the 4-mm segment in the interrogated region and used as the index representing the size of the LCP.
Virtual histology intravascular ultrasound
The methods of the IVUS examination have been described previously, and we have previously reported the presence of necrotic core in patients with early atherosclerosis [14, 15] . The IVUS examination was performed after intracoronary administration of 100-200 mg nitroglycerine. A 20-MHz, 2.9-Fr monorail, electronic Eagle Eye Gold IVUS catheter (Volcano Therapeutics, Rancho Cordova, California, USA) was advanced into the LAD, and automatic pullback at 0.5 mm/s was performed. The four VH-IVUS plaque components were color-coded as follows: dark green (fibrous), light green (fibrofatty), red (necrotic core), and white (dense calcium); they are reported as the area or percentage of plaque area. All imaging data were stored digitally in a dedicated console (In-Vision Gold; Volcano Therapeutics).
Patients were scheduled to undergo IVUS of the same study vessel at 6 months. Volumetric IVUS data were presented as total volume per lesion length (mm 3 /mm) for correcting the differences of lesion length among the patients.
Optical coherence tomography image acquisition and analysis
For acquisition of OCT images, C7-XR OCT Intravascular Imaging System (St Jude Medical, St Paul, Minnesota, USA) was used. The intracoronary OCT technique has been described previously [16] [17] [18] [19] . Imaging catheter (Dragonfly; St Jude Medical) was advanced into the proximal midsegment of the LAD, and automatic pullback at a speed of 20 mm/s (100 frames/s) was initiated in concordance with blood clearance by infusion of contrast media. All OCT images were digitally stored and analyzed offline using proprietary software (St Jude Medical). Each segment was evaluated in terms of plaque type and additional two OCT-based characteristics including macrophage image and microchannels. Plaques were classified into three categories according to plaque type: lipid, calcific, or fibrous [20] . A lipid plaque has low signal region with diffuse border. A plaque with lipid occupying two or more quadrants of any crosssectional area within the plaque was considered as a lipid-rich plaque. A fibrous plaque was defined as a lesion with homogeneous high backscattering region. A calcified plaque was defined as a lesion with a signal-poor or heterogeneous region with a sharply delineated border. Macrophage image was defined as signal-rich distinctor confluent punctate regions that exceed the intensity of background speckle noise, which are accompanied by high behind signal attenuation [21, 22] . In plaques with macrophage image, angles of macrophage arc were measured using a protractor centered on the lumen at every frame. Maximum angle and longitudinal length were recorded. Microchannels were defined as intraplaque signal-voiding tubular structures with a diameter of 50-300 μm which were sharply delineated and identified on more than three consecutive cross-sectional OCT images. Maximum number and longitudinal length of microchannels were measured [16, 17, 19, 21, 23] . Longitudinal length was measured on longitudinal view.
Laboratory testing
Patients underwent basic blood testing (complete blood count, serum electrolytes, and lipid profile) as well as assessment of Lp-PLA 2 activity and high-sensitivity C-reactive protein (hs-CRP) levels using baseline and follow-up stored samples. The latex particle-enhanced immunoturbidimetric assay (Roche Diagnostics, Indianapolis, Indiana, USA) was used to measure hs-CRP, whereas an enzymatic colorimetric activity assay (Diazyme Laboratories, Poway, California, USA) with a five-point calibration curve (0-400 nmol/min/ml) on the Cobas 6000/c501 instrument (Roche Diagnostics) was used to measure Lp-PLA 2 activity.
Statistical analysis
Statistical analysis was performed using the JMP 8.0 Software and SAS 9.3 (SAS Institute, Cary, North Carolina, USA). Continuous variables were presented as mean SD if normally distributed and were compared with the unpaired Student's t-test. Variables not normally distributed were presented as median (first, third quartile) and compared with the Mann-Whitney rank-sum test. Categorical variables were presented as frequency (percentage) and compared with Pearson's χ 2 -test. Comparison within the groups were done using Wilcoxon signed-rank test for nonparametric data. The intraagreement (κ) was calculated to present the intraobserver variability for identification of microchannel on OCT, and intraclass correlation coefficient were used to describe intraobserver reproducibility for plaque volume on VH-IVUS. All statistical tests were two-sided, and a P value of 0.05 was considered to be statistically significant.
Results
Baseline characteristics
Mean age of patients in the darapladib and placebo group was 54.7 11.2 and 52.9 10.1 years, respectively (Table 1) . Baseline characteristics are listed in Table 1 . Other than baseline low-density lipoprotein (LDL), there was no significant difference in medication use (Table 1) , or baseline laboratory values in both groups (P > 0.05) ( Table 2 ).
On follow-up, there was no significant difference in total cholesterol level, LDL levels, or hs-CRP levels, but there was a significant decrease in Lp-PLA 2 activity levels and a greater increase in high-density lipoprotein in the darapladib compared with the placebo group (P < 0.001) (Table 3) .
Overall, there were no safety concerns, with no deaths. There were five serious adverse events, including a patient with chest pain who was admitted and recuperated with nitroglycerin, another with recurrent angina secondary to anomalous pulmonary vein and endothelial dysfunction, a third requiring preponement of tricuspid valve repair and anomalous pulmonary vein repair secondary to chest pain, and a patient with chest pain who required angiography. Independent review suggested none of the events were related to the study drug.
Near-infrared spectroscopy
There was no significant difference in mean length of the LAD interrogated by NIRS pullback (56.92 16.30 vs. 62.68 20.11 mm; P = 0.450). In the analysis of chemogram, there were no significant differences in overall LCBI, LCBI/L, and maxLCBI 4 mm between both groups at baseline and at 6-month follow-up (Table 4 ). In patients with repeat NIRS, LCBI/L, and maxLCBI 4 (Fig. 1 ). There were no significant changes in median percentage of color blocks including yellow, tan, orange, and red blocks, respectively. NIRS findings at baseline and follow-up are detailed in Table 4 .
Virtual histology intravascular ultrasound
At baseline and follow-up, plaque volume and necrotic core component measurements were comparable between treatment groups in the region of interests (Table 5) . Corrected plaque volume and necrotic core volume were not significantly different during the follow-up period within those receiving darapladib and placebo (Fig. 2) .
We also analyzed difference between group in absolute changes and percent change between baseline and 6 months. There were no significant difference in absolute change of corrected plaque volume, percent change of corrected plaque volume, absolute change of necrotic core component volume, and percent change of NC component volume (Table 5) .
Optical coherence tomography
OCT findings at baseline and follow-up are shown in Table 6 . The OCT imaging demonstrated about 91 versus 88% of lipid-rich plaques, 27 versus 50% of macrophage images, and 64 versus 63% of microchannel in darapladib and placebo group, respectively, at baseline. There were no significant differences in lipid-rich plaque angle, macrophage image, and microchannel between two groups at baseline and follow-up. Changes in parameters describing plaque vulnerability were nonsignificant. Macrophage images angle [ − 9.5°(− 25.53°, 12.68°) vs. − 16.7°(− 28.6°, − 4.8°), P = 0.489] was not significantly different in both groups, but microchannel length [0 (− 4.4, 0.2) mm vs. 0.8 (− 0.15, 1.9) mm, P = 0.08] showed a trend toward shorter length in darapladib group compared with placebo group (Fig. 3) .
Intraobserver variability κ-Coefficient for the presence or absence of microchannel by OCT was 0.77 (95% CI: 0.35-1.00) and intraclass correlation coefficient for plaque volume by VH-IVUS was 0.88 
Discussion
The current study demonstrates that 6 months of endogenous Lp-PLA 2 inhibition does not affect the degree of atherosclerosis or plaque characteristics in patients with early coronary atherosclerosis. The current study therefore does not support a role for Lp-PLA 2 inhibition in attenuating atherosclerotic plaque progression in humans.
Darapladib was not associated with a change in lipid core burden by NIRS, atheroma volume and necrotic core proportion as measured by VH-IVUS, and microenvironment like macrophage, and microchannel by OCT showed no significant improvement on follow-up.
Preliminary data supported potential role of Lp-PLA 2 in the pathogenesis of atherosclerosis because of its role in inflammation [1] . In particular, Lp-PLA 2 could have played a role in early atherosclerosis. Previous studies from our group and others have demonstrated that early coronary atherosclerosis is associated with elevated Lp-PLA 2 levels and enhanced activity of Lp-PLA 2 across the coronary circulation, supporting a particular role for this molecule in early coronary atherosclerosis [8, 9, 24] . In a study of patients with early coronary atherosclerosis undergoing coronary endothelial function testing, abnormal coronary vasoreactivity, an early marker of atherosclerosis, was found to be strongly associated with elevated Lp-PLA 2 levels [25] . Although there is strong evidence consistent with a role for Lp-PLA 2 in this early process, we found that Lp-PLA 2 inhibition did not affect early atherosclerotic plaques in our study. This is consistent with results from two large randomized clinical trials, which did not show a reduction in major coronary events with darapladib inhibition [26, 27] . These studies investigated the clinical efficacy and safety of darapladib on a background of optimal medical therapy in patients with stable coronary heart disease and acute coronary syndrome, respectively. However, darapladib was not not associated with reduction in the primary endpoint of major adverse cardiovascular events in one study, and major coronary events or in major adverse cardiovascular events in postacute coronary syndrome patients.
We explored the role of darapladib in altering plaque characteristics by analyzing atheroma through multiple imaging modalities. During Lp-PLA 2 inhibition, (i) lipid core burden analyzed by NIRS also remained without change.
(ii) Atheroma volume and necrotic core proportion observed by VH-IVUS did not change in most of the patients either. (iii) Finally, microenvironmental features like macrophages, or microchannels by OCT showed no significant improvement in most of the patients. Previously, the IBIS-2 trial showed that Lp-PLA 2 inhibition over 12 months prevented necrotic core expansion, a key determinant of plaque vulnerability [11] . Necrotic core volume increased significantly during the study period among patients receiving placebo, but remained unchanged in the darapladib group. Lipid core was not improved with Lp-PLA 2 inhibition either. Our results are consistent with these data, except that necrotic core volume in our study did not change in placebo group. The LDL cholesterol level was relatively lower and highdensity lipoprotein cholesterol level was higher in our Data are represented in median (Q1, Q3) and mean SD. LCBI, lipid core burden index; LCBI/L, LCBI per length of the scanned artery; maxLCBI4 mm, lipid core burden index for any of the 4-mm segment. Intracoronary plaque and darapladib Choi et al. 109 patient population compared with those in the IBIS-2 trial population. In addition, a difference in follow-up interval may further account for the discrepancy in our findings. Notably, our study used multiple imaging modalities to identify the precise change of atherosclerotic plaque, which is a key strength, but none of them identified a prominent effect of the drug.
Intravascular imaging has played an important role in advancing our understanding of the pathophysiology of coronary artery plaque. NIR, OCT, and VH-IVUS are representative and complementary tools for the coronary plaque imaging in clinical practice. VH-IVUS has been frequently used to obtain detailed information about the composition and characteristics of coronary atherosclerotic plaques [28] . The greatest advantage of OCT is its highresolution images that can provide detailed observation of the vulnerable lipid core plaque. It characterizes not only plaque components but also coronary microstructures like macrophages and the vasa vasorum [17, 29] . OCT especially has an important role in evaluating the vasa vasorum in early atherosclerosis [30] . The NIRS system excels in its ability to discriminate tissue-type difference on the basis of chemical composition in coronary autopsy specimens and in-vivo validation studies [13] . Thus, NIRS has been proven to be the only available tool capable of reliably detecting the lipid core plaque.
In the present study, there were no changes in the atherosclerotic component of plaque by VH-IVUS, OCT, and NIR. These results are consistent with larger randomized clinical studies that have also shown no reduction in major adverse cardiovascular events with Lp-PLA 2 inhibition. Our findings further underscore the multiple complex and redundant pathways involved in inflammation that make it difficult to target a particular component, the atherosclerotic process.
Our data support adherence with the medication, as there is significant reduction in Lp-PLA 2 activity in the darapladib arm. There was no significant reduction in hs-CRP levels with darapladib use, however, potentially suggesting that the degree of inhibition was insufficient to reduce hs-CRP levels and allow plaque attenuation. This is also consistent with larger randomized studies suggesting no improvement in cardiovascular outcomes with darapladib.
Our study has several strengths. This is the first pathophysiologic study examining the effect of darapladib on plaque composition in patients with coronary endothelial dysfunction and is an important addition exploring the mechanistic aspects of Lp-PLA2 to the clinical trials. Second, the prospective and randomized nature of our study and the scientific rigor with which the study was conducted confer high validity. Third, unlike many previous studies, we have been able to ascertain medication adherence by assessing the degree of Lp-PLA 2 inhibition. Fourth, although each intravascular imaging modality has its own strengths and weaknesses, our study uses three separate imaging modalities in conjunction with an experienced core laboratory to optimize yield of reproducible and generalizable results.
Study limitations
In turn, our study has several limitations. First, our sample size is small and may limit our findings. Second, this is a single-center study with a limited follow-up interval of 6 months, potentially reducing the detectability of beneficial effect. Third, patients were not recruited on the basis of their baseline Lp-PLA 2 activity levels, which might have helped in appropriate screening and randomization of patients. Moreover, although VH-IVUS was used extensively in previous large studies such as PROSPECT, its use in clinical practice is declining [31] . Although the evaluation of macrophages and microchannels with OCT has been studied, it is difficult, and there are potential pitfalls that may limit interpretation and reproducibility. In addition, the diagnostic accuracy for OCT-derived macrophages was not higher than expected, and thus the ability of OCT to accurately characterize macrophages needs to be further investigated and clarified in future studies. This is an inherent limitation of OCT that needs to be further evaluated. The study of macrophages and microchannels with OCT can pose several difficulties, and this must be kept in mind as we interpret images and may affect reproducibility of data [32] [33] [34] . This is an inherent limitation to this methodology.
Conclusion
Lp-PLA 2 has been associated with vascular inflammation, early atherosclerosis, and cardiovascular disease. The current study demonstrates that 6 months of Lp-PLA 2 inhibition did not change plaque volume or composition, including lipid core burden and plaque vulnerability, when analyzed with multimodality intravascular imaging. These findings do not support the role of Lp-PLA 2 inhibition in attenuating atherosclerotic plaque progression in humans.
